Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Phase 2

Terminated

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: dalteparin
Drug: lenalidomide
Drug: dexamethasone
Other: laboratory biomarker analysis

First Posted Date: 2012-01-26

Last Posted Date: 2017-11-29

Lead Sponsor: University of Southern California

Target Recruit Count: 13

Registration Number: NCT01518465

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Vorinostat
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2011-12-29

Last Posted Date: 2016-05-10

Lead Sponsor: Tiziana Marangon

Registration Number: NCT01501370

Locations: 🇮🇹
Clinica di Ematologia, A.O.U. Ospedali Riuniti, Ospedale Umberto I di Ancona, Ancona, Italy
🇮🇹
U.O.S. di Ematologia, Ospedale Mazzoni, Ascoli Piceno, Italy
🇮🇹
Dh ematologia, A.O.U. Careggi, Firenze, Italy

and more 5 locations

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Phase 2

Completed

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: High Dose Methylprednisolone (HDMP)
Drug: Ofatumumab
Drug: Lenalidomide

First Posted Date: 2011-12-22

Last Posted Date: 2021-04-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 29

Registration Number: NCT01497496

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

Phase 2

Active, not recruiting

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: High Dose Methylprednisolone (HDMP)
Drug: Ofatumumab
Drug: Lenalidomide

First Posted Date: 2011-12-22

Last Posted Date: 2024-11-29

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 45

Registration Number: NCT01496976

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Doxorubicin
Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cyclophosphamide

First Posted Date: 2011-11-29

Last Posted Date: 2019-03-01

Lead Sponsor: Vejle Hospital

Target Recruit Count: 35

Registration Number: NCT01481194

Locations: 🇩🇰
Department of Hematology, Vejle, Denmark

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Phase 3

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab-CHOP
Drug: Rituximab
Drug: Rituximab-CVP
Drug: Lenalidomide
Drug: Rituximab-Bendamustine

First Posted Date: 2011-11-22

Last Posted Date: 2024-06-20

Lead Sponsor: Celgene

Target Recruit Count: 255

Registration Number: NCT01476787

Locations: 🇺🇸
Local Institution - 53003, Southfield, Michigan, United States
🇺🇸
Local Institution - 51103, Houston, Texas, United States
🇺🇸
Local Institution - 51203, Dallas, Texas, United States

and more 11 locations

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: lenalidomide
Biological: rituximab

First Posted Date: 2011-11-16

Last Posted Date: 2024-07-16

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 38

Registration Number: NCT01472562

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

and more 1 locations

Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: lenalidomide

First Posted Date: 2011-11-02

Last Posted Date: 2022-05-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT01463670

Locations: 🇺🇸
North Shore LIJ, New Hyde Park, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Stamford Hospital, Stamford, Connecticut, United States

and more 8 locations

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Adult Mixed Cellularity Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
Adult Nodular Sclerosis Hodgkin Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma
Adult Lymphocyte Predominant Hodgkin Lymphoma

Interventions: Drug: panobinostat
Drug: lenalidomide

First Posted Date: 2011-10-27

Last Posted Date: 2017-11-14

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT01460940

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Phase 2

Active, not recruiting

Conditions: Leukemia
Lymphoma

Interventions: Drug: Rituximab
Drug: Lenalidomide

First Posted Date: 2011-10-05

Last Posted Date: 2024-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT01446133

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy